Merck & Co., Inc. Board of Directors

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Mr. Robert M. Davis J.D.

Mr. Robert M. Davis J.D.

Chairman, President & CEO

Mr. Sanat Chattopadhyay

Mr. Sanat Chattopadhyay

Executive VP & President of Merck Manufacturing Division

Mr. Richard R. DeLuca Jr.

Mr. Richard R. DeLuca Jr.

Executive VP & President of Merck Animal Health

Mr. Peter Dannenbaum

Mr. Peter Dannenbaum

Vice President of Investor Relations

Mr. David Michael Williams

Mr. David Michael Williams

Executive VP and Chief Information & Digital Officer

Ms. Cristal N. Downing

Ms. Cristal N. Downing

Executive VP and Chief Communications & Public Affairs Officer

Mr. Dalton E. Smart III

Mr. Dalton E. Smart III

Senior VP of Finance, Principal Accounting Officer & Global Controller

Ms. Jennifer L. Zachary J.D.

Ms. Jennifer L. Zachary J.D.

Executive VP & General Counsel

Dr. Dean Y. Li M.D., Ph.D.

Dr. Dean Y. Li M.D., Ph.D.

Executive VP & President of Merck Research Laboratories

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.